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Abstract
Nicotinic acetylcholine receptors (nAChRs) are ligand-gated ion channels mediating fundamental
physiological activities in the nervous system and have become important targets for drug design. For a long
time, the acetylcholine binding protein (AChBP) has been used as a surrogate to study the nAChR structure-
function. Taking advantage of more than 100 AChBP crystal structures in the Protein DataBank (PDB), we
explored the relationship between the size, efficiency, and efficacy of nAChR ligands and the C-loop
movement. We found that the size of the ligand is correlated with the opening of the C-loop, which can be
used in selecting AChBP crystal structures with appropriate C-loop opening to be used for nAChR ligand
docking. Ligand size and C-loop opening are reversely correlated with the ligand efficiency rather than the
binding affinity. Ligand efficiency could be accurately predicted using simple computational docking, giving a
correlation coefficients (R2) up to 0.73. The efficacy of nAChR ligands might be related to ligand size, C-loop
opening, and ligand efficiency. Results from this study are useful for engineering the binding affinity and
efficacy of nAChR ligands.
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Nicotinic acetylcholine receptors (nAChRs) are ligand-gated ion channels involved in fast 
synaptic transmission and physiological activities in the nervous system.1 nAChRs belong to 
the cys-loop receptor family, which also includes glycine, serotonin (5-HT3), γ-amino butyric 
acid type A (GABAA) receptors, and a zinc-activated ion channel.2 There are many different 
nAChR subtypes with preferential distribution in the nervous system where they mediate 
different physiological processes.1 Malfunction of the nAChR is related to neurological 
disorders such as Parkinson’s disease, Alzheimer’s disease, schizophrenia, pain, depression, 
and memory loss.1,3,4 Hence, nAChRs are important targets for drug design.1,4 In vertebrates, 
there are 17 nAChR subunits consisting of α1-α10, β1-β4, γ, δ, and ε. nAChRs are composed 
of five subunits, with each subunit divided into three domains: an extracellular domain 
(ECD), a transmembrane domain (TMD), and an intracellular domain (ICD) (Figure 1A,B). 
The ligand binding site is formed by the ECD of two adjacent subunits (Figure 1C), 
consisting of loops A, B, and C of the principal subunit and the β-sheet of the complementary 
subunit. Recently, the published crystal structure of human α4β2 nAChR (PDB code: 5KXI)5 
showed that the agonist, nicotine, is deeply capped into the ligand binding site with the 
nicotine positively charged N group oriented to the center of the nAChR aromatic box, 
forming a cation−π interaction with residue W156. For a long time, the crystal structure of 
acetylcholine binding protein (AChBP), a homologue of the nAChR ECD, has been used as a 
template to study nAChR structure and function.6 Crystal structures of the AChBP in apo, 
complexed with full agonists, partial agonists, and antagonists, demonstrate that the C-loop of 
the binding site is very flexible to accommodate the wide spectra of nAChR ligands (Figure 
1D,E, Table S1).7−17 Agonist binding triggers conformational changes in cys-loop receptors, 
leading to opening of the channel and, consequently, a flux of ions through the channel pore. 
The starting step for nAChR activation by an agonist is capping of the binding site C-loop 
into closed conformation.18−21 The conformational state of the C-loop might be related to the 
functional state of the nAChR. The ligand binding sites of AChBP are highly plastic, 
allowing binding of various molecules ranging from small neurotransmitters to large peptide 
neurotoxins, such as α-conotoxins and snake toxins.7,17,22 Analysis of the AChBP bound with 
various ligands of nAChR indicated that the opening of the C-loop bound with full agonist is 
comparable to or even more closed than that bound with partial agonist, but the latter is 
remarkably more closed than that bound with antagonist (Figure 1D), in line with the results 
of Brams et al.8 It tempts us to assume that a relationship might exists between the 
conformational states of the C-loop with ligand size, efficiency, and efficacy. In this study, 
we statistically analyzed 48 crystal structures of AChBP bound with different nAChR ligands 
(Table S2, Figure S1)8−17,23−37 to explore the aforementioned relationship between the nAChR 
ligands and the C-loop. 
 
METHODS 
Ligand Size and C-Loop Opening Calculations.  
Crystal structures of AChBP bound with nAChR ligands with known binding affinity (PDB 
ID: 1UV6, 1UW6, 2WNL, 2BYQ, 3WTN, 3WTL, 2BYS, 3WIP, 3U8J, 3ZDG, 4BQT, 
3ZDH, 4AFT, 3U8K, 4B5D, 2ZJV, 3C84, 3U8L, 3C79, 3U8M, 2WNC, 2WN9, 3U8N, 
2WNJ, 4AFH, 2XNT, 4ALX, 2PGZ, 2XNU, 2XYS, 2W8F, 2W8G, 2X00, 2XYT, 2BYR, 
2WZY, 2C9T, 2BR8, 4BFQ, 4DBM, 4QAA, 4QAB, 4QAC, 2Y54, 2Y56, 2Y57, 2Y58 and 
1UX2) were selected and downloaded from the Protein DataBank (PDB, 
http://www.rcsb.org). The number of heavy atoms for the nAChR ligands was calculated 
using ChemDraw (Figure S1), and the opening of the C-loop of the AChBP was calculated 
using Visual Molecular Dynamics (VMD).38 Ligand Binding Affinity and Ligand Efficiency. 
The ligand binding affinity (∆G) was calculated using the equation 
∆G = −RT ln Kd           (1) 
where R = 8.314 J·mol−1·K−1, T = 300 K, and Kd is the equilibrium dissociation constant. 
Ligand efficiency (∆g) was determined using the equation 
∆g = ∆G/Nheavy atoms          (2) 
where ∆G is the binding free-energy change (or ligand binding affinity) and Nheavy atoms is 
the number of heavy or non-hydrogen atoms.39−41 
AutoDock Binding Affinity Calculation.  
Structures of AChBP were extracted from PDB entries 1UV6, 1UW6, 2WNL, 2BYQ, 
3WTN, 3WTL, 2BYS, 3WIP, 3U8J, 3ZDG, 4BQT, 3ZDH, 4AFT, 3U8K, 4B5D, 2ZJV, 
3C84, 3U8L, 3C79, 3U8M, 2WNC, 2WN9, 3U8N, 2WNJ, 4AFH, 2XNT, 4ALX, 2PGZ, 
2XNU, 2XYS, 2W8F, 2W8G, 2X00, 2XYT, 2BYR, 2WZY, 2C9T, 2BR8, 4BFQ, 4DBM, 
4QAA, 4QAB, 4QAC, 2Y54, 2Y56, 2Y57, 2Y58, 1UX2, 2XZ5, 2YMD, 2YME, 3SH1, 
3SIO, 4AFG, 2ZJU, 3WTH, 4UM1, 4UM3, 3WTI, and 3WTJ.  Ligands were extracted from 
the crystal structures, and hydrogen atoms were added. Docking of nAChR ligands to AChBP 
was performed using AutoDock Tools (ADT)4.2.42 Gasteiger charges were used, and 
nonpolar hydrogens of the macromolecule and ligand were merged. A grid box with 
dimensions of 40 Å × 40 Å × 40 Å and a grid spacing of 0.375 Å was set up and centered on 
the “aromatic box” between two adjacent subunits of the AChBP. For docking of peptide 
ligands, a grid box with dimensions of 60 Å × 60 Å × 60 Å was applied. Docking was 
performed using a Lamarckian genetic algorithm (LGA), with the receptor treated as rigid. 
The number of LGAs was set using the default values. The produced conformation with 
minimum binding energy was selected for the analysis. 
MOE Binding Affinity Calculation.  
Molecular docking was performed using MOE with the AMBER10:EHT force field.43 
AChBP crystal structures used for the ADT calculations above were utilized. The induced fit 
docking approach was applied with consideration of the side chain flexibility of residues at 
the binding site. The ligand binding site was defined using the bound ligands in the crystal 
structures. Ten docking conformations of the ligands were produced, and the best scored 
conformation with minimum binding energy was selected for analysis. 
MMPBSA Binding Affinity Calculation.  
The binding energy calculation module of MMPBSA44 implemented in AMBER1645 was 
used to calculate the binding affinities of the nAChR ligand posed to AChBP using MOE or 
nAChR ligands in the crystal structures of AChBP. Here, only the minimum energy 
conformation determined in MOE was used for energy calculation using MMPBSA. Briefly, 
the internal dielectric and external dielectric constants were set to 2.0 and 80.0, respectively, 
with a probe radius of 1.4 Å, a grid spacing set to 0.5 Å, and ionic strength set to 0.15 M/L.46 
 
RESULTS AND DISCUSSION 
All ligands were regularly distributed when they were ranked based on their size and opening 
of the AChBP C-loop bound with the corresponding ligands. Ligand size could be 
characterized using the number of heavy atoms (or non-hydrogen atoms), surface area, ligand 
volume, or molecular weight (Figure S2), among which the number of heavy atoms was most 
facile to obtain. Here, the number of heavy atoms was selected to represent the ligand size. 
Ranking nAChR ligands based on their size in order from low to high showed that the full 
agonists were mostly at the left (low heavy atom number), the antagonists were at the right 
(high heavy atom number), and the partial agonists were in the middle (Figure 2A, Table S2). 
Notably, the distribution boundary between the partial agonists and antagonists is not clearly 
defined. Indeed, some of the nAChR ligands are antagonists despite their comparable or 
smaller size than that of the partial agonists.15−17 Interestingly, these ligands are rich of 
aromatic rings that could appropriately orient their position to form π−π stacking interactions 
with the aromatic residues of the binding site, and the C-loop was usually stabilized in an 
open conformation (Figure S3).  
Similarly, using the distance of the C-loop opening as the ranking parameter of the ligands 
(from smallest to largest shift), the agonists had the least and modest impact on the C-loop 
movement, respectively. The antagonists, however, resulted in the largest shift of the C-loop 
opening (Figure 2B, Table S2). However, unlike the ligand size distribution profile, the 
boundary between the agonists and antagonists is more clearly defined. Thus, C-loop opening 
measurement is a more reliable indicator to differentiate the agonists from the antagonists of 
the nAChR.  
The correlation between the C-loop shift and nAChR agonist efficacy though, is unclear 
(Figure 2B). Indeed, there remains controversy over the correlation between the opening of 
the C-loop and agonist efficacy of the nAChR.8,24,37 It is challenging to use the limited 
number of AChBP crystal structures to thoroughly understand the structure−function 
relationships of nAChR agonists. The AChBP crystal structure is homologus to the ECD of 
nAChR, and therefore, the conformational state of the C-loop on AChBP might not be 
exactly the same to that of the nAChR as trivial differences exist.47,48 In addition, nAChR 
agonists can behave differently at different nAChR subtypes. For instance, nicotine activates 
other subtypes of nAChR while antagonizing the α9α10 nAChR subtype.49,50 In addition, 
choline is a known α7 nAChR subtype-selective agonist but acts as a partial agonist for some 
other nAChR subtypes.51 The ligand efficacy of the nAChR is related to not only the ligand 
binding and the induced conformation perturbation at the binding site but also the gating 
processes of the receptor. Overall, the opening of the C-loop is correlated with the ligand size 
of nAChR, with a correlation coefficient (R2) of 0.54 (Figure 2C). Exclusion of five ligands 
(in the dashed frame of Figure 2C) with distinctive structure or unusual binding manner 
(Figure S3) from the analysis improved the R2 value to 0.86 (Figure 2D). These five ligands 
are relatively small, but they are rich in aromatic rings. These rings are often linked through 
flexible rational bonds, and they can adjust their conformation to play a role of supporter 
(Figure S3A−D) or they can form π−π stacking interactions with each other to produce a 
“ligand cluster” (Figure S3E). The C-loop of the binding site is very flexible, thus allowing it 
to adjust its conformation or opening to accommodate various nAChR ligands of different 
sizes (Figure 3). Therefore, it is not surprising to observe the correlation between the ligand 
size and C-loop opening induced by the corresponding ligands. However, it has to be noted 
that ligands, usually antagonists of the nAChRs, with distinctive structure or unusual binding 
manner (Figure S3) can still stabilize the open conformation of the C-loop by forming π−π 
stacking interactions with aromatic residues of the binding site despite their relatively small 
size in comparison to the partial agonists (Figure S3, Table S2). As a result, there is not clear 
distinction between the partial agonists and antagonists with distinctive structure or unusual 
binding manner when they are ranked based on the size. Nevertheless, in general, there is 
good agreement between the size of the ligand and the opening of the C-loop, which can be 
predicted using the ligand size as the input variable. As shown in Figure 2D, the opening of 
the C-loop (Å) can be predicted using eq 3 
f (x) = 0.11x + 8.9  
(n = 43, R2 = 0.86, SD = 2.33, q2 = 10.88, F = 247.159)     (3) 
where x is the number of heavy atoms. 
To date, over 100 crystal structures of AChBP bound with different nAChRs ligands are 
available in the PDB, providing sufficient models of the C-loop movement to understand the 
ligand nAChR structure−activity relationship.16,52 Correct selection of the crystal structures is 
essential for accurate docking models of nAChR ligands. Here, we proposed the use of eq 3 
in selecting suitable ligand-bound AChBP crystal structures for generation of docking 
models. To evaluate the accuracy of eq 3 in predicting the opening of the C-loop of AChBP, 
we randomly chose four nAChR ligands (Table 1) with known AChBP-bound crystal 
structures from the PDB22,52−54 and compared the calculated opening of the Cloop for each 
ligand using eq 3 with their respective crystal structures. For the four ligands, the calculated 
values of the C-loop opening are similar to the values determined from ligand-bound crystal 
structures, with 2−3 Å deviation (Table 1).  
Crystal structures of AChBP with a C-loop opening close to our predicted values were then 
selected for nAChR ligand docking. Docking studies suggested that the binding modes of the 
four nAChR ligands can be correctly predicted using the selected AChBP crystal structures 
(Figure 4) with a root-mean-square deviation (RMSD) of less than 2 Å. In contrast, the 
binding orientation of these ligands significantly deviated from their respective crystal 
structures (RMSD > 3 Å) when AChBP structures with a substantially open or closed C-loop 
were used for docking (Figure S4). Thus, the conformational state of the C-loop and selection 
of the correct crystal structures for nAChR molecular docking or as a homology modeling 
template should be considered in future modeling studies of the nAChR ligands.  
Ranking of the ligands based on their binding affinity resulted in irregular distribution 
(Figure 5A, Table S2). In contrast, using the binding efficiency of the agonists and 
antagonists as the ranking parameter, most of the full agonists had the highest binding 
efficiency followed by the partial agonists and the antagonists with the lowest efficiency 
(Figure 5B, Table S2). Thus, the binding efficiency of the ligands rather than their binding 
affinities could be used to differentiate the agonists from the antagonists of the nAChR.  
Our analysis also indicated that no correlation was found between ligand size and binding 
affinity (R2 = 0.05) (Figure 5C), whereas a strong linear correlation was identified (R2 = 0.7) 
between the logarithm of the number of the heavy atoms (or ligand size) and ligand 
efficiency (Figure 5D). Indeed, comparison of protein−ligand binding affinities for over 8000 
ligands with 28 protein targets shows that the ligand efficiency rather than average ligand 
binding affinities is correlated with molecular size.55 Large ligands usually form more  
contacts with the receptor than smaller size ligands, whereas the binding affinities of the 
former do not overwhelm that of the latter (Figure 5A, Table S2). Thus, it is not rational to 
improve the binding affinity of the nAChR ligands merely by increasing the ligand size. 
Instead, optimization of their structure and functional groups might be a more feasible choice. 
In contrast, ligand efficiency is reversely correlated with the logarithm of ligand size in a 
linear way. Therefore, ligand size should be considered as the priority when the ligand 
efficiency of the nAChR ligands are modified in future drug design.  
Comparison of the ligand binding affinity with the opening of the C-loop suggested that there 
was no correlation (R2 = 0.00048) (Figure 5E). The ligand efficiency, however, is well 
reversely correlated with the opening of the C-loop (R2 = 0.53) (Figure 5F). nAChR ligands 
with higher efficiency tend to cap the C-loop into a more closed conformation and vice versa, 
in line with the observations that full and partial agonists tend to capture the conformation of 
the C-loop in fully and partially closed states, respectively. In comparison, the antagonists 
mostly stabilize the C-loop of the nAChR into an open conformation (Figure 2B).8,24  
Ligand efficiency, simply defined as ligand binding in terms of free energy per heavy 
atom,39,40 could be useful in deciding the potential further optimization of particular “hits” 
and chemical scaffolds. The efficacy of a ligand, on the other hand, is generally determined 
by the ligand’s ability to promote a quantifiable biological response upon binding.56 We 
found that there might be some correlation between ligand efficiency and ligand efficacy for 
nAChR ligands (Figure 5B). In comparison to ligand size, ligand efficiency might be a more 
reliable indicator to differentiate the agonists from the antagonists of the nAChR as ligand 
efficiency takes into account the size and binding affinity of the ligand (Equation 2). Indeed, 
a small size ligand with very poor binding affinity cannot function as a full agonist, until it 
binds to the nAChR and caps the C-loop into the closed conformation. 
Interestingly, we found that ligand efficiencies could be simply predicted using 
computational docking.8−17,23−37,57−60 As shown in Figure 6A,B, the predicted ligand 
efficiencies using MOE and ADT are well correlated with the experimentally determined 
ligand efficiencies (R2 = 0.57 and 0.73, respectively) (Figure S5). We also evaluated the 
performance of MMPBSA at predicting ligand efficiency, and we found that its performance 
is comparable to ADT but a little inferior to MOE (Figure 6C,D and Figure S6). Overall, the 
ligand efficiency could be well predicted using molecular docking, an extremely fast and 
economical binding affinity calculation method. 
 
CONCLUSIONS 
In this study, we statistically analyzed 48 crystal structures of the AChBP bound with 
different nAChR ligands with known binding affinities to explore the relationship between 
nAChR ligand size, efficiency, and efficacy and C-loop opening. We found that the opening 
of the C-loop of the crystal structure of AChBP is correlated with the ligand size except for a 
few ligands with distinctive structure or with unusual binding modes. For a given ligand, the 
opening of the bound C-loop could be predicted based on an equation derived from statistical 
analysis of 43 nAChR ligands bound to the crystal structures of AChBP. Crystal structures of 
the AChBP with C-loop opening most close to the calculated values were selected for nAChR 
ligand docking, and the predicted pose of the ligand is well superimposed with that 
determined in the crystal structure. Additionally, we found that ligand efficiency rather than 
affinity was correlated with the size of the ligand and C-loop opening, and ligand efficiency 
could be predicted using the computational docking method. Full agonists, partial agonists, 
and antagonists of the nAChR were regularly distributed in major when they were ranked 
based on their size, C-loop opening, or the ligand efficiency. Ligand size, C-loop opening, 
and ligand efficiency might have certain amplitudes of correlations with the ligand efficacy, 
and they are implicated to be useful to distinguish the agonists and antagonists of the nAChR.  
In summary, establishing the relationship between ligand size, C-loop opening, ligand 
efficiency, and ligand efficacy is important for not only accurate prediction of the binding 
modes of the nAChR ligands but also in differentiation of the agonists from the antagonists of 
the nAChR. As the number of AChBP crystal structures bound with different nAChR ligands 
continues to increase, it will give rise to more accurate knowledge-based computational 
methods for rational design of ligands targeting the cys-loop receptors. 
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Figure 1. Crystal structures of human α4β2 nAChR (PDB ID: 5KXI) with bound nicotine 
molecules and AChBPs (PDB ID: 1UV6, 2BYS, 2BYQ, 3WTN, 3WIP, 3U8J, 4BQT, 4AFT,  
2XNT, 2W8F, 2BYR, 2C9T). (A) Side view of the human α4β2 nAChR with two nicotine 
molecules (magenta) bound to the ECD binding site (dashed frame). The α4 and β2 subunits 
are colored blue and gold, respectively. (B) Top view of the human α4β2 nAChR, with (C) 
the ligand binding site magnified (dashed frame). The ligand binding site is comprised of 
loops A, B, and C of the α4 (principal) subunit and β-sheet of the β4 (complementary) 
subunit. (D) Superimposed crystal structures of full agonist (red) (PDB ID: 1UV6, 2BYS, 
2BYQ, 3WTN, 3WIP), partial agonist (green) (PDB ID: 3U8J, 4BQT, 4AFT), and antagonist 
(blue) (PDB ID: 2XNT, 2W8F, 2BYR, 2C9T) bound- AChBP, with the C-loop highlighted 
(dashed frame). For clarity, only one AChBP subunit is shown. (E) Magnification of the 












Figure 2. Correlation between nAChR ligand size and C-loop opening. (A) Size-based 
ranking of nAChR full agonists (red), partial agonists (green), antagonists (blue), and ligands 
with unknown property (white) in order from small to large. (B) Distribution of the opening 
of the C-loop bound with full agonists (red), partial agonists (green), antagonists (blue), and 
ligands with unknown property (white) in order from minimum to maximum (mean ± SEM, n 
= 5). Then AChR ligand size and C-loop opening correlation coefficient score (R2) for (C) all 
ligands is 0.54, and (D) that after removal of ligands with special binding profiles (dashed 
frame from C) is 0.86. 
 
 
Figure 3. Schematic profile of ligand-bound nAChR. (A) Full agonist (nicotine), (B) partial 
agonist (Tropisetron), and (C) antagonist (α-conotoxin ImI) binding to the nAChR ligand 
binding site. The binding site is formed by the principal (blue) and complementary (magenta) 



















Figure 4. Comparison of computationally determined binding of nAChR ligands (gray) to 
AChBP (cyan) with crystallographically determined binding of the same ligands (purple-
blue) to AChBP (green). Two ligand-bound AChBP crystal structures with a C-loop opening 
most similar to the calculated values were selected and used for the docking of (A,E) 4P0, 













Figure 5. Correlation of the nAChR ligand binding free energy (∆G) and ligand efficiency 
(∆g) to ligand size and C-loop opening. Ranking distribution of nAChR full agonists (red), 
partial agonists (green), antagonists (blue), and ligands with unknown property (white) based 
on their (A) ∆G and (B) ∆g in order from low to high. The correlation coefficient score (R2) 
for (C) ∆G and ligand size is 0.05, and (D) that for ∆g and ligand size is 0.70. The R2 value 
for C-loop opening correlation with (E) ∆G and (F) ∆g is 0.048 and 0.53, respectively. The 
ligand binding affinities and efficacies were determined using equations ∆G = −RT ln Kd and 
∆g = ∆G/Nheavy atoms (Nheavy atoms, number of heavy atoms), respectively. The Kd values were 
determined using experimental approaches. In total, 61 compounds were docked into AChBP 
using ADT, while 59 nonpeptide compounds were selected for docking using MOE. MOE is 

















Figure 6. Correlation of computationally determined nAChR ligand efficiency (∆g) with 
those determined using experimental approaches. Ligand ∆g calculated using (A) ADT, (B) 
MOE, and (C,D) MMPBSA method. For (C), MMPBSA calculation was directly performed 
on the crystal structures of AChBP bound with nAChR ligands, and in (D), MMPBSA was 
used to recalculate the binding affinities of the nAChR ligands docked using MOE. Ligand 
efficiency was calculated using the equation, ∆g = ∆G/Nheavy atoms (Nheavy atoms, number of 
heavy atoms), where ∆G is the calculated binding affinity of the nAChR ligands using ADT, 








Table 1. Comparison of computationally and experimentally determined C-loop opening of 
nAChR ligand-bound AChBP 

















4P0 12 10.22 3WIP 10.68 4ZJS 12.2 0.71 
   3U8J 10.76   2.39 
40P 51 14.51 2W8F 15.89 4XHE 17.67 0.52 
   2XNT 15.75   0.78 
41J 50 14.4 2BYR 15.46 4XK9 17.11 0.35 
   2XYT 14.47   3.21 
TxIA[A10L] 114 21.44 4BFQ 18.68 2UZ6 19.87 1.88 
   2C9T 19.83   1.78 
aPredicted C-loop opening using eq 3. bPDB ID of the two crystal structures of AChBP with 
similar C-loop opening to the predicted values selected for docking. cC-loop opening of the 
selected crystal structures. dPDB ID of the crystal structure bound with the docked ligand. eC-
loop opening of the crystal structure bound with the docked ligand. fRMSD between the 
predicted ligand orientation and ligand orientation in the crystal structure of d. 
 
 
 
 
